You are in: eMedicine Specialties > Physical Medicine and Rehabilitation > UPPER LIMB MUSCULOSKELETAL CONDITIONS Biceps TendinopathyArticle Last Updated: Jun 22, 2006AUTHOR AND EDITOR INFORMATIONAuthor: Peter Gonzalez, MD, Instructor, Spine and Sports Fellow, Department of Physical Medicine and Rehabilitation, University of Colorado Health Sciences Center Peter Gonzalez is a member of the following medical societies: American Academy of Physical Medicine and Rehabilitation, North American Spine Society, and Physiatric Association of Spine, Sports and Occupational Rehabilitation Coauthor(s): William J Sullivan, MD, Assistant Professor, Pain Medicine Fellowship Director, Director of Medical Student Education, Department of Physical Medicine and Rehabilitation, University of Colorado at Denver Health Sciences Center; Keith AJ Sequeira, MD, Associate Director of Spinal Cord Medicine, Assistant Professor, Department of Physical Medicine and Rehabilitation, Parkwood Hospital, University of Western Ontario; Patrick J Potter, MD, FRCP(C), Director of Spinal Cord Injury Program, Associate Professor, Department of Physical Medicine and Rehabilitation, Parkwood Hospital, Lawson Health Research Institute Editors: Robert J Kaplan, MD, Associate Professor, Department of Physical Medicine and Rehabilitation, University of Kansas School of Medicine and Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Patrick M Foye, MD, FAAPMR, FAAEM, Associate Professor of Physical Medicine and Rehabilitation, Co-Director of Musculoskeletal Fellowship, Co-Director of Back Pain Clinic, Director of Coccyx Pain (Tailbone Pain, Coccydynia) Service, UMDNJ-New Jersey Medical School; Kelly L Allen, MD, Consulting Staff, Department of Physical Medicine and Rehabilitation, Lourdes Regional Rehabilitation Center, Our Lady of Lourdes Medical Center; Robert H Meier III, MD, Director, Amputee Services of America, Presbyterian St Luke's Hospital; Consulting Staff, North Valley Rehabilitation Hospital, Kindred Hospital, North Suburban Hospital Author and Editor Disclosure Synonyms and related keywords: biceps tendinitis, biceps tendinosis, bicipital tenosynovitis INTRODUCTIONBackgroundBiceps tendinopathy describes pain and tenderness in the region of the biceps tendon. The biceps musculotendinous junction is particularly susceptible to overuse injuries, especially in individuals performing repetitive lifting activities. This condition is often diagnosed incorrectly and confused with rotator cuff tendinopathy. Biceps tendinopathy is rarely seen in isolation. It coexists with other pathologies of the shoulder, including rotator cuff tendinopathy and tears, shoulder instability, and imbalances of the dynamic stabilizers. Of patients with biceps tendinopathy, 95% have "impingement syndrome" as their primary diagnosis (Curtis, 1993). PathophysiologyHistorically, all disorders of the biceps tendon have been termed biceps tendinitis. Recent evidence suggests that degenerative changes in the tendon occur without inflammation. In acute cases, an inflammatory pathology may still be a valid explanation of biceps tendon pain. Tendinitis describes inflammation of the tendon and the paratendon. This is usually caused by chronic overload, leading to microscopic tears in the tendon, which triggers an inflammatory response. Peritendinitis is the inflammation of the paratendon or tendon sheath. This usually occurs as a result of a direct injury or irritation in which the tendon rubs over a bony prominence; this is referred to as a tenosynovitis. Tendinosis is a histological definition describing degenerative changes in the tendon (Puddu, 1976). Macroscopic evaluation of a degenerative tendon reveals disorganized tissue that is soft and yellow or brown (mucoid degeneration) (Rees, 2006). The microscopic appearance reveals degenerative changes to collagen with fibrosis (Rees, 2006). Inflammatory mediators are not usually present in tendinosis. The term tendinopathy refers to the clinical presentation of a symptomatic tendon. The underlying pathology, degenerative or inflammatory, is not considered in this definition. Three etiologies of tendinopathy have been described. The mechanical theory of tendinopathy states that repetitive loading of the tendon results in microscopic degeneration. Fibroplasia occurs within the tendon, resulting in scar tissue. The vascular theory states that tendon degeneration occurs as a result of focal areas of vascular compromise. A newer theory is based on neural modulation. This theory focuses on the assumption of neurally mediated mast cell degranulation and release of substance P. More studies are needed to more clearly understand the relationship between the peripheral nervous system and tendinopathies (Rees, 2006). The anatomy of the biceps brachii muscle is important in understanding biceps tendinopathy. The biceps brachii has 2 heads. The short head arises from the tip of the coracoid process of the scapula. The long head arises from the supraglenoid tubercle of the scapula and the superior labrum runs through the intertubercular groove between the greater and lesser tubercles of the humerus. Proximally, the long head of the biceps acts as a shoulder stabilizer through depression of the humeral head (Kumar, 1989). The 2 heads join together in the distal arm to form one strong tendon, which inserts on the radial tuberosity on the upper end of the radius. Distally, the tendon gives off the bicipital aponeurosis (an expansion that blends with the flexor forearm muscles, extending to the ulna). The biceps brachii is innervated by the musculocutaneous nerve (C5, C6). The actions of the biceps brachii muscle is flexion of the elbow, supination of the forearm, humeral head depression, and shoulder flexion (short head primarily). FrequencyUnited StatesBiceps tendinopathy is a common condition, but the exact frequency is unknown. CLINICALHistoryDiagnosis is primarily clinical. Patient history suggests the diagnosis.
Physical
Causes
DIFFERENTIALSAdhesive Capsulitis Biceps Rupture Brachial Neuritis Cervical Spondylosis Rheumatoid Arthritis Rotator Cuff Disease
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Ibuprofen (Ibuprin, Advil, Motrin) |
|---|---|
| Description | DOC for mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing prostaglandin synthesis. |
| Adult Dose | 200-400 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d |
| Pediatric Dose | <6 months: Not established 6 months to 12 years: 4-10 mg/kg/dose PO tid/qid >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity to ibuprofen, other NSAIDs, or aspirin; avoid in peptic ulcer disease, recent GI bleeding or perforation, renal insufficiency, and high risk of bleeding |
| Interactions | May decrease effects of loop diuretics with coadministration; coadministration with anticoagulants may increase PT (monitor and watch for signs of bleeding); may increase serum lithium levels and risk of methotrexate toxicity; probenecid may increase toxicity |
| Pregnancy | A - Safe in pregnancy |
| Precautions | Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy |
| Drug Name | Naproxen (Anaprox, Naprelan, Naprosyn) |
|---|---|
| Description | For relief of mild to moderate pain; inhibits inflammatory reactions and pain by decreasing activity of cyclo-oxygenase, which is responsible for prostaglandin synthesis. |
| Adult Dose | 375-500 mg PO bid |
| Pediatric Dose | <2 years: Not recommended >2 years: 10 mg/kg/d PO in divided doses |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency |
| Interactions | Probenecid may increase toxicity; coadministration with ibuprofen may decrease effects of loop diuretics; coadministration with anticoagulants may prolong PT (watch for signs of bleeding); NSAIDs may increase serum lithium levels and risk of methotrexate toxicity (eg, stomatitis, bone marrow suppression, nephrotoxicity) |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in patients with syndrome of ASA, nasal polyps, and asthma; acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion, risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrant further evaluation and may require discontinuation of drug |
| Drug Name | Ketoprofen (Oruvail, Orudis, Actron) |
|---|---|
| Description | For relief of mild to moderate pain and inflammation. Small dosages are indicated initially in patients with small body size, elderly patients, and those with renal or liver disease. Doses >75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patient for response. |
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 300 mg/d |
| Pediatric Dose | <3 months: Not established 3 months to 12 years: 0.1–1 mg/kg PO q6-8h >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | May decrease effects of loop diuretics with coadministration; coadministration with anticoagulants may increase PT (monitor and watch for signs of bleeding); may increase serum lithium levels and risk of methotrexate and phenytoin toxicity; probenecid may increase toxicity of NSAIDs |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy |
| Drug Name | Celecoxib (Celebrex) |
|---|---|
| Description | Primarily inhibits COX-2. COX-2 is considered an inducible isoenzyme, induced by pain and inflammatory stimuli. Inhibition of COX-1 may contribute to NSAID GI toxicity. At therapeutic concentrations, COX-1 isoenzyme is not inhibited, thus incidence of GI toxicity, such as endoscopic peptic ulcers, bleeding ulcers, perforations, and obstructions, may be decreased when compared to nonselective NSAIDs. Seek lowest dose for each patient. Neutralizes circulating myelin antibodies through anti-idiotypic antibodies; down-regulates proinflammatory cytokines, including INF-gamma; blocks Fc receptors on macrophages; suppresses inducer T and B cells and augments suppressor T cells; blocks complement cascade; promotes remyelination; may increase CSF IgG (10%). Has a sulfonamide chain and is primarily dependent upon cytochrome P450 enzymes (a hepatic enzyme) for metabolism. |
| Adult Dose | 200-400 mg/d PO qd or divided bid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | CYP450 2C9 substrate; coadministration with fluconazole may cause increase in celecoxib plasma concentrations because of inhibition of celecoxib metabolism; coadministration of celecoxib with rifampin may decrease celecoxib plasma concentrations |
| Pregnancy | X - Contraindicated in pregnancy |
| Precautions | May cause fluid retention and peripheral edema; caution in compromised cardiac function, hypertension, conditions predisposing to fluid retention; caution in severe heart failure and hyponatremia because may deteriorate circulatory hemodynamics; NSAIDs may mask usual signs of infection; caution in the presence of existing controlled infections; evaluate therapy when symptoms or lab results suggest liver dysfunction |
Pain control is essential to quality patient care. Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients with tendinitis.
| Drug Name | Acetaminophen (Tylenol, Panadol, Aspirin Free Anacin) |
|---|---|
| Description | DOC for pain in patients with documented hypersensitivity to aspirin, NSAIDs, diagnosed with upper GI disease, or on oral anticoagulants. |
| Adult Dose | 325-650 mg PO q4-6h or 1,000 mg tid/qid; not to exceed 4 g/d |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose PO q4-6h prn; not to exceed 2.6 g/d >12 years: 325-650 mg PO q4h; not to exceed 5 doses in 24 h |
| Contraindications | Documented hypersensitivity |
| Interactions | Rifampin can reduce analgesic effects; coadministration with barbiturates, carbamazepine, hydantoins, and isoniazid may increase hepatotoxicity |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Hepatotoxicity can occur, in chronic alcoholics, with various dose levels of acetaminophen; severe or recurrent pain or high or continued fever may indicate a serious illness |
| Drug Name | Capsaicin (Dolorac, Capsin, Zostrix) |
|---|---|
| Description | Derived from plants of Solanaceae family. May render skin and joints insensitive to pain by depleting substance P in peripheral sensory neurons. |
| Adult Dose | Cream: Apply to skin tid/qid for 3-4 consecutive wk and evaluate efficacy (not to exceed 4 applications/d) |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity; broken or irritated skin |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | For external use only; avoid contact with eyes; do not use tight bandage; discontinue use if condition worsens or symptoms persist for 14-28 d |
Deterrence/Prevention:
Complications:
Prognosis:
Patient Education:
| Media file 1: The Speed test: The examinee is pointing to where the pain usually is produced for a positive test. | |
![]() | View Full Size Image | Media type: Photo |
Article Last Updated: Jun 22, 2006